under the radar, page-2

Call me sceptical, but I think there is something suspiciously quiet about this lack of build up before the announcement of phase 111 results. I suspect there maybe either something unconvincing about the ATC performance, or the size of the future profitability of the drug is questionable.
I do not believe AVX is that far underneath the radar of knowledgeable and well resourced investors.
I suspect the average punter does not know the full story of the risks here, which larger investors are aware of, and taking into account, by staying away.
Just my opinion.